Brainstorm Cell Therapeutics Inc. filed a Form 10-Q with the SEC for the quarterly period ended September 30, 2026, disclosing condensed consolidated financial statements and ongoing going-concern and delisting risk disclosures.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $163 thousand as of September 30, 2026, up from $29 thousand at December 31, 2025, according to the filing.
  • Total current assets: The company reported total current assets of $453 thousand at September 30, 2026, compared with $307 thousand at December 31, 2025.
  • Prepaid expenses decline: Prepaid expenses and other current assets fell to $101 thousand from $192 thousand at December 31, 2025.
  • Restricted cash: Restricted cash decreased to $185 thousand at September 30, 2026 from $247 thousand at December 31, 2025.
  • Shares outstanding: As of November 11, 2026, common stock outstanding totaled 14,259,377 shares at a par value of $0.00005 per share.
  • OTCQB trading and going-concern risk: The filing identifies the company's common stock trading on the OTCQB Venture Market following Nasdaq delisting, and lists the ability to continue as a going concern among its stated risk factors.

Brainstorm's Financial Position and Key Risks as of September 30, 2026

According to the Form 10-Q filed with the SEC for the quarterly period ended September 30, 2026, Brainstorm Cell Therapeutics Inc. reported cash and cash equivalents of $163 thousand, up from $29 thousand at December 31, 2025. Total current assets rose to $453 thousand from $307 thousand over the same period. Other accounts receivable increased to $189 thousand from $86 thousand, while prepaid expenses and other current assets declined to $101 thousand from $192 thousand at year-end 2025.

Among long-term assets, the filing discloses restricted cash of $185 thousand at September 30, 2026, down from $247 thousand at December 31, 2025, and a right-of-use asset is also listed on the balance sheet. The company is classified as a non-accelerated filer and a smaller reporting company. The filing states that common stock outstanding was 14,259,377 shares as of November 11, 2026, at a par value of $0.00005 per share.

The filing notes that Brainstorm's common stock trades on the OTCQB Venture Market following its delisting from Nasdaq, and explicitly names "our ability to continue as a going concern" among the risks and uncertainties it identifies. The company develops the NurOwn technology platform and has conducted clinical trials targeting neurodegenerative conditions including amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis, and Alzheimer's disease, as described in the filing. The company's forward-looking statements are its own and are subject to the cautionary language included in the quarterly report.

What Was Disclosed

Brainstorm Cell Therapeutics filed its quarterly report for the period ended September 30, 2026, disclosing unaudited condensed consolidated balance sheet data, share count as of November 11, 2026, OTCQB trading status following Nasdaq delisting, going-concern risk, and ongoing legal proceedings and clinical development activities involving its NurOwn technology platform.